Welcome to the eight-part series on liquid biopsy titled, “Utility of Cell-free DNA in the Clinic: Current State and Future Directions.” This series covers a range of concepts from the basic biological underpinnings of cell-free DNA (cfDNA) to new and specific advances (and the clinical implications thereof) in the diagnostic and prognostic use of cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA). You may complete the webinars any order, you can claim CME/CMLE for each section of the program.
Learning Objectives:
Following the full program, participants will be able to:
- Describe the components of cell-free DNA (cfDNA) and its dynamics in health and disease.
- Discuss opportunities for circulating tumor DNA (ctDNA) assessment in oncology practices.
- Discuss limitations of ctDNA assessment in oncology practices.
- Identify challenges, and list possible solutions, unique to cfDNA assay validation.
- Compare biologic and technical aspects of cfDNA tests for early detection of cancer.
- Summarize current standards and practices in non-invasive prenatal screening
- Recognize opportunities and pitfalls of non-invasive microbial assessment.
Webinars Included in the bundle
- Basic Biology and Detection of Cell-Free DNA
- Practical Analytical and Clinical validation Strategies for Cell-Free Tumor DNA Assays
- Opportunities and Challenges Toward the Clinical Application of ctDNA MRD Testing in Solid Cancers
- Current and Emerging Applications of cell-free DNA Tumor Tests
- Utility of Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Infections
- Cell free (cf)DNA-based Prenatal Screening: Lessons Learned and Future Strategies
- Cell-free DNA: predictive tissue injury maps in COVID-19
- Utility of Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Infections
Duration: ~8.0 hours of video
Program Launched: April 2023
CME/CMLE Credit Available: 8.0 hours
Last day to claim CME or CMLE Credit: December 31, 2023
Faculty
Continuing Education Credit
Maximum CME credit available: 8.0
Maximum CMLE credit available: 8.0
**Continuing Education Credit must be claimed by December 31, 2023
Physicians (ACCME)
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Association for Molecular Pathology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live to enduring activity for a maximum of 8.00 AMA PRA Category 1 CreditsTM (1.00 CE for each webinar). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical Laboratory Education (CMLE)
This activity has been planned and implemented in accordance with the Amedco and joint provider-ship of the ASC and the Association for Molecular Pathology (AMP). Course number 7013
Supported by an educational grant from AstraZeneca and by educational funding provided by Amgen.
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation
